These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 22642398)

  • 1. Gene networks modified by sulphonylureas in beta cells: a pathway-based analysis of insulin secretion and cell death.
    Magnusson NE; Dyrskjøt L; Grimm D; Wehland M; Pietsch J; Rungby J
    Basic Clin Pharmacol Toxicol; 2012 Oct; 111(4):254-61. PubMed ID: 22642398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical efficacy of glimepiride].
    Kaneko T; Sakamoto N
    Nihon Rinsho; 1997 Nov; 55 Suppl():152-7. PubMed ID: 9434460
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of exposure of human islet beta-cells to normal and high glucose levels with or without gliclazide or glibenclamide.
    Del Guerra S; D'Aleo V; Lupi R; Masini M; Bugliani M; Boggi U; Filipponi F; Marchetti P
    Diabetes Metab; 2009 Sep; 35(4):293-8. PubMed ID: 19502091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effect of sulfonylureas on production of reactive oxygen species and apoptosis in cultured pancreatic beta-cell line, MIN6.
    Sawada F; Inoguchi T; Tsubouchi H; Sasaki S; Fujii M; Maeda Y; Morinaga H; Nomura M; Kobayashi K; Takayanagi R
    Metabolism; 2008 Aug; 57(8):1038-45. PubMed ID: 18640379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different sulfonylureas induce the apoptosis of proximal tubular epithelial cell differently via closing K
    Zhang R; Zhou X; Shen X; Xie T; Xu C; Zou Z; Dong J; Liao L
    Mol Med; 2018 Sep; 24(1):47. PubMed ID: 30180807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treating diabetes today: a matter of selectivity of sulphonylureas.
    Seino S; Takahashi H; Takahashi T; Shibasaki T
    Diabetes Obes Metab; 2012 Jan; 14 Suppl 1():9-13. PubMed ID: 22118705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The insulin-secreting and proliferative activity of established islet cells in the presence of sulfonylurea].
    Balabolkin MI; Timofeev AV; Danilova TI; Zhuleva LIu; Ol'shanskaia AA
    Biull Eksp Biol Med; 1992 Oct; 114(10):406-8. PubMed ID: 1288706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Forearm vascular reactivity is differentially influenced by gliclazide and glibenclamide in chronically treated type 2 diabetic patients.
    Wascher TC; Boes U
    Clin Physiol Funct Imaging; 2005 Jan; 25(1):40-6. PubMed ID: 15659079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
    Clark HE; Matthews DR
    Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glitazone-like action of glimepiride and glibenclamide in primary human adipocytes.
    Mayer P; Haas B; Celner J; Enzmann H; Pfeifer A
    Diabetes Obes Metab; 2011 Sep; 13(9):791-9. PubMed ID: 21477042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding of sulphonylureas to plasma proteins - A KATP channel perspective.
    Proks P; Kramer H; Haythorne E; Ashcroft FM
    PLoS One; 2018; 13(5):e0197634. PubMed ID: 29772022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Caveolin-1 is essential for glimepiride-induced insulin secretion in the pancreatic betaTC-6 cell line.
    Puddu A; Salani B; Cordera R; Viviani GL; Maggi D
    Biochem Biophys Res Commun; 2008 Oct; 375(2):235-7. PubMed ID: 18703018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cooperation between cAMP signalling and sulfonylurea in insulin secretion.
    Shibasaki T; Takahashi T; Takahashi H; Seino S
    Diabetes Obes Metab; 2014 Sep; 16 Suppl 1():118-25. PubMed ID: 25200305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular effects of conventional sulfonylureas and glimepiride.
    Geisen K; Végh A; Krause E; Papp JG
    Horm Metab Res; 1996 Sep; 28(9):496-507. PubMed ID: 8911987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic antidiabetic sulfonylureas in vivo: reversible effects on mouse pancreatic beta-cells.
    Remedi MS; Nichols CG
    PLoS Med; 2008 Oct; 5(10):e206. PubMed ID: 18959471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reflections on the sulphonylurea story: A drug class at risk of extinction or a drug class worth reviving?
    Cordiner RLM; Pearson ER
    Diabetes Obes Metab; 2019 Apr; 21(4):761-771. PubMed ID: 30471177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of sulphonylureas in the management of type 2 diabetes mellitus.
    Rendell M
    Drugs; 2004; 64(12):1339-58. PubMed ID: 15200348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin exocytosis in Goto-Kakizaki rat beta-cells subjected to long-term glinide or sulfonylurea treatment.
    Kawai J; Ohara-Imaizumi M; Nakamichi Y; Okamura T; Akimoto Y; Matsushima S; Aoyagi K; Kawakami H; Watanabe T; Watada H; Kawamori R; Nagamatsu S
    Biochem J; 2008 May; 412(1):93-101. PubMed ID: 18254725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The in vivo interaction between gliclazide and glibenclamide and insulin on glucose disposal in the rat.
    Tanira MO; Furman BL
    Pharmacol Res; 1999 May; 39(5):349-56. PubMed ID: 10328992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of K+ channels and stimulation of insulin secretion by the sulfonylurea, glimepiride, in relation to its membrane binding in pancreatic islets.
    Schwanstecher M; Mnner K; Panten U
    Pharmacology; 1994 Aug; 49(2):105-11. PubMed ID: 7972319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.